Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 5,931 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Breathing, Mouth, Lung Function Decreased
Interventions: Impulse Oscillometer; Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Pain, Postoperative, Gingival Diseases
Interventions: amnion-chorion membrane, Sutures; Device · Procedure
Lead sponsor: Harvard Medical School (HMS and HSDM); Other
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Advanced Solid Tumors, Cowden Syndrome
Interventions: BEZ235; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 9
States / cities: Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 6 more

Conditions: Premature Birth
Interventions: Oral Feed, Usual care; Dietary Supplement
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 32 Weeks and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Congestive Heart Failure
Interventions: Tolvaptan; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 161
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 131 more

Conditions: Multiple Sclerosis
Interventions: BIIB061; Drug
Lead sponsor: Biogen; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pregnancy-associated Gingivitis
Interventions: counseling; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 16 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Type 2 Diabetes Mellitus
Interventions: ORMD-0801 (qd), ORMD-0801 (bid), ORMD-0801 (tid), Placebo; Drug · Other
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tustin, California

Conditions: Malnutrition
Interventions: ONS QIP, ONS Standard Feeding; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 18 Years and older
Enrollment: 2,386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Barrington, Illinois • Libertyville, Illinois • Oak Lawn, Illinois + 1 more

Conditions: Sjogren's Syndrome, Dry Eye, Neurotrophic Keratitis
Interventions: Eye Exam; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Generalized Moderate Chronic Periodontitis, Generalized Severe Chronic Periodontitis, Periodontal Diseases
Interventions: Scaling and root planing, Er:YAG Laser, Hand instruments; Procedure · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Carcinoma, Transitional Cell
Interventions: Tesetaxel; Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Dental Plaque
Interventions: Iodine, water; Drug · Other
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Northfield, New Jersey

Conditions: Myelofibrosis, Polycythemia Vera, Thrombocytosis
Interventions: Ruxolitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Rochester, Minnesota • Houston, Texas

Conditions: Dyslipidaemias, Dyslipidemias
Interventions: 10mg atorvastatin, 80mg atorvastatin, GSK1292263 Placebo, 100mg GSK1292263, 300mg GSK1292263, 800mg GSK1292263, 10mg ezetimibe, Washout; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: Anniston, Alabama • Chula Vista, California • Stockton, California + 15 more

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer, Refractory, Progression, Diffuse Large B Cell Lymphoma, Multiple Myeloma, Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Plasma-Cell, Myelomatosis, Plasma Cell Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: BMF-219; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 17
States / cities: Irvine, California • Los Angeles, California • Sacramento, California + 13 more

Conditions: Gingival Recession
Interventions: Tunnel + AlloDerm, Tunnel + Novomatrix; Procedure
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Rheumatoid Arthritis
Interventions: suspension IR, CR 1, CR 2, CR 3; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Oral Health Related Quality of Life (OHRQoL)
Interventions: Botanical A, Botanical B, Vehicle (Placebo solution); Dietary Supplement
Lead sponsor: Access Business Group; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions: CC-486; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 4
States / cities: New York, New York • Cleveland, Ohio • Houston, Texas + 1 more

Conditions: Crohn Disease
Interventions: CCX282-B; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 14
States / cities: Los Angeles, California • Golden, Colorado • Littleton, Colorado + 11 more

Conditions: Food Hypersensitivity
Interventions: Not listed
Lead sponsor: ORA, Inc.; Industry
Eligibility: 5 Years to 35 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Brain and Central Nervous System Tumors
Interventions: carmustine, cisplatin, etoposide, radiation therapy; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 18
States / cities: Scottsdale, Arizona • Peoria, Illinois • Cedar Rapids, Iowa + 15 more

Conditions: Sialorrhoea
Interventions: oxybutynin and clonidine oral solution treatment A, oxybutynin and clonidine oral solution treatment B, oxybutynin and clonidine oral solution treatment C, oxybutynin and clonidine oral solution treatment D; Drug
Lead sponsor: Orient Pharma Co., Ltd.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Bingham Farms, Michigan

Search by objective public record fields.

Evaluating Deep Breathing in Health Participants Using a Device Called Impulse Oscillometry

Effect of Using Placental Membranes on Healing and Post-op Pain After Gum Surgery

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Preterm Functional Early Enteral Development (FEED) Trial on Respiratory Support

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

Single-Dose Study of a New Formulation of BIIB061

A Study to Evaluate Associations Between Gingivitis and Pregnancy Outcomes

A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

Quality Improvement Program (QIP) to Reduce 30-Day Readmission in Malnourished Hospitalized Patients

Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye

Treatment of Periodontitis With Er:YAG Laser

Tesetaxel for Previously Treated Patients With Bladder Cancer

Clinical Research Study Efficacy of a Prototype Oral Rinse

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Root Coverage Comparing an Allograft to a Bovine Xenograft

Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers

New Functional Ingredient for Oral Care

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease

Food Allergy Challenge Diagnostic Study

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma

A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease